NeuroVive Pharmaceutical AB organizacji Rok IPO
Jaka jest wartość Rok IPO organizacji NeuroVive Pharmaceutical AB?
Wartość Rok IPO organizacji NeuroVive Pharmaceutical AB to 2018
Jaka jest definicja Rok IPO?
Pierwsza oferta publiczna jest rodzajem oferty publicznej, w której akcje spółki zazwyczaj sprzedawane są inwestorom instytucjonalnym, którzy z kolei sprzedają się ogółowi społeczeństwa, na giełdzie papierów wartościowych, po raz pierwszy.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Rok IPO firm w Health Care sektor na OTC w porównaniu do NeuroVive Pharmaceutical AB
Czym się zajmuję organizacja NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Firmy z rok ipo podobne do NeuroVive Pharmaceutical AB
- Wartość Rok IPO organizacji Mediawan SA to 2017
- Wartość Rok IPO organizacji Southern to 2017
- Wartość Rok IPO organizacji Polytec Hldg Ag Inh. Eo 1 to 2017
- Wartość Rok IPO organizacji Roots Sustainable Agricultural Technologies to 2017
- Wartość Rok IPO organizacji Galena Mining to 2017
- Wartość Rok IPO organizacji MVC Capital Inc to 2017
- Wartość Rok IPO organizacji NeuroVive Pharmaceutical AB to 2018
- Wartość Rok IPO organizacji Bermele plc to 2019
- Wartość Rok IPO organizacji Twin River Worldwide to 2019
- Wartość Rok IPO organizacji Contel Technology to 2019
- Wartość Rok IPO organizacji GraniteShares 3x Long Diageo Daily ETC to 2019
- Wartość Rok IPO organizacji Pinterest Inc to 2019
- Wartość Rok IPO organizacji Ferrellgas Partners, L.P to 2019